Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19

According to numerous recent publications, the COVID-19 patients have lymphopenia, higher infection-related biomarkers and several elevated inflammatory cytokines (i.e. tumor necrosis factor (TNF)-α, interleukin IL-2R and IL-6). The total number of B cells, T cells and NK cells are significantly dec...

Descripción completa

Detalles Bibliográficos
Autores principales: Angelopoulou, Athina, Alexandris, Nikos, Konstantinou, Evangelia, Mesiakaris, Konstantinos, Zanidis, Charilaos, Farsalinos, Konstantinos, Poulas, Konstantinos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309930/
https://www.ncbi.nlm.nih.gov/pubmed/32846644
http://dx.doi.org/10.1016/j.envres.2020.109858
_version_ 1783549270505291776
author Angelopoulou, Athina
Alexandris, Nikos
Konstantinou, Evangelia
Mesiakaris, Konstantinos
Zanidis, Charilaos
Farsalinos, Konstantinos
Poulas, Konstantinos
author_facet Angelopoulou, Athina
Alexandris, Nikos
Konstantinou, Evangelia
Mesiakaris, Konstantinos
Zanidis, Charilaos
Farsalinos, Konstantinos
Poulas, Konstantinos
author_sort Angelopoulou, Athina
collection PubMed
description According to numerous recent publications, the COVID-19 patients have lymphopenia, higher infection-related biomarkers and several elevated inflammatory cytokines (i.e. tumor necrosis factor (TNF)-α, interleukin IL-2R and IL-6). The total number of B cells, T cells and NK cells are significantly decreased. RNA viruses, SARS-CoV-2 included, hit the innate immune system in order to cause infection, through TLRs 3, 7 and 8. Imiquimod is an immune-stimulator that activates TLR 7 and can be used to enhance the innate and adaptive immunity. Preclinical and clinical trials are proposed.
format Online
Article
Text
id pubmed-7309930
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-73099302020-06-23 Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19 Angelopoulou, Athina Alexandris, Nikos Konstantinou, Evangelia Mesiakaris, Konstantinos Zanidis, Charilaos Farsalinos, Konstantinos Poulas, Konstantinos Environ Res Article According to numerous recent publications, the COVID-19 patients have lymphopenia, higher infection-related biomarkers and several elevated inflammatory cytokines (i.e. tumor necrosis factor (TNF)-α, interleukin IL-2R and IL-6). The total number of B cells, T cells and NK cells are significantly decreased. RNA viruses, SARS-CoV-2 included, hit the innate immune system in order to cause infection, through TLRs 3, 7 and 8. Imiquimod is an immune-stimulator that activates TLR 7 and can be used to enhance the innate and adaptive immunity. Preclinical and clinical trials are proposed. Elsevier Inc. 2020-09 2020-06-23 /pmc/articles/PMC7309930/ /pubmed/32846644 http://dx.doi.org/10.1016/j.envres.2020.109858 Text en © 2020 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Angelopoulou, Athina
Alexandris, Nikos
Konstantinou, Evangelia
Mesiakaris, Konstantinos
Zanidis, Charilaos
Farsalinos, Konstantinos
Poulas, Konstantinos
Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19
title Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19
title_full Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19
title_fullStr Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19
title_full_unstemmed Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19
title_short Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19
title_sort imiquimod - a toll like receptor 7 agonist - is an ideal option for management of covid 19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309930/
https://www.ncbi.nlm.nih.gov/pubmed/32846644
http://dx.doi.org/10.1016/j.envres.2020.109858
work_keys_str_mv AT angelopoulouathina imiquimodatolllikereceptor7agonistisanidealoptionformanagementofcovid19
AT alexandrisnikos imiquimodatolllikereceptor7agonistisanidealoptionformanagementofcovid19
AT konstantinouevangelia imiquimodatolllikereceptor7agonistisanidealoptionformanagementofcovid19
AT mesiakariskonstantinos imiquimodatolllikereceptor7agonistisanidealoptionformanagementofcovid19
AT zanidischarilaos imiquimodatolllikereceptor7agonistisanidealoptionformanagementofcovid19
AT farsalinoskonstantinos imiquimodatolllikereceptor7agonistisanidealoptionformanagementofcovid19
AT poulaskonstantinos imiquimodatolllikereceptor7agonistisanidealoptionformanagementofcovid19

Ejemplares similares